Description
A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from anterior nasal and nasopharyngeal swab specimens
- COVID-19
– Anterior nasal swab specimen − Sensitivity 93.8 %, Specificity 100%
– Nasopharyngeal − Sensitivity 93.1 %, Specificity 100%
- Flu A – Sensitivity 91.4%, Specificity 95.7%
- Flu B – Sensitivity 87.6%, Specificity 95.9%
- FDA Emergency Use Authorization (EUA)
- Visually read in 15 minutes
- Flocked nasopharyngeal swab for superior specimen collection and patient comfort
Features :
- Hygienic Product : Not Specified
- Allergy : Not Specified
Specifications
- UPC:Not Specified
- GTIN/ITF Barcode : Not Specified
- Units of Measure : Not Specified
- Overall Product Length : Not Specified in
- Overall Product Width : Not Specified in
- Overall Product Height : Not Specified in
- Weight Capacity : Not Specified lbs
- Actual Product Weight : 0.80
- Product Assembly : Not Specified
- Product Installation : Not Specified
- Country of Origin : Not Specified
- Case QTY : Not Specified/case
- Case Weight : Not Specified
- Ships Via Freight : No
- Proposition 65 Warning : Not Specified